Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2011

Open Access 01-12-2011 | Research article

Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia

Authors: Albert Bolstad, Ole A Andreassen, Jan I Røssberg, Ingrid Agartz, Ingrid Melle, Lars Tanum

Published in: BMC Psychiatry | Issue 1/2011

Login to get access

Abstract

Background

Although not recommended in treatment guidelines, previous studies have shown a frequent use of more than one antipsychotic agent among patients with schizophrenia. The main aims of the present study were to explore the antipsychotic treatment regimen among patients with schizophrenia in a catchment area-based sample and to investigate clinical characteristics associated with antipsychotic combination treatment.

Methods

The study included 329 patients diagnosed with schizophrenia using antipsychotic medication. Patients were recruited from all psychiatric hospitals in Oslo. Diagnoses were obtained by use of the Structured Clinical Interview for DSM-IV Axis I disorders (SCID-I). Additionally, Global Assessment of Functioning (GAF), Positive and Negative Syndrome Scale (PANSS) and number of hospitalisations and pharmacological treatment were assessed.

Results

Multiple hospital admissions, low GAF scores and high PANSS scores, were significantly associated with the prescription of combination treatment with two or more antipsychotics. The use of combination treatment increased significantly from the second hospital admission. Combination therapy was not significantly associated with age or gender. Regression models confirmed that an increasing number of hospital admission was the strongest predictor of the use of two or more antipsychotics.

Conclusions

Previous hospital admissions and disease severity measured by high PANSS scores and low GAF scores, predict the use of antipsychotic combination treatment in patients with schizophrenia. Future studies should further explore the use of antipsychotic drug treatment in clinical practice and partly based on such data establish more robust treatment guidelines for patients with persistently high symptom load.
Literature
1.
Owen RR, Fisher EP, Kirchner JE, Thrust CR, Williams K, Cuffel BJ, et al: Clinical Practice Variations in Prescribing Antipsychotics for Patients with Schizophrenia. Am J Medical Quality. 2003, 18 (4): 140-145. 10.1177/106286060301800402.CrossRef
2.
National Institute for Health and Clinical Excellence: Schizophrenia, Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE, (UK). 2002
3.
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry. 2004, 16 (2 Suppl): 1-56. Second
4.
Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al: The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003. SchizophrBull. 2004, 30 (2): 193-217.
5.
Wolff-Menzler C, Hasan A, Malchow B, Falkai P, Wobrock T: Combination Therapy in the Treatment of Schizophrenia. Pharmacopsychiatry. 2010, 43: 122-129. 10.1055/s-0030-1249097.CrossRefPubMed
6.
Weinmann S, Koesters M, Becker T: Effects of implementation of psychiatric guidelines on provider performance and patient outcome: a systematic review. Acta Psychiatr Scand. 2007, 115: 420-433. 10.1111/j.1600-0447.2007.01016.x.CrossRefPubMed
7.
Leucht S: Psychiatric treatment guidelines: doctors' non-compliance or insufficient evidence?. Acta Psychiatr Scand. 2007, 115: 417-419. 10.1111/j.1600-0447.2007.01030.x.CrossRefPubMed
8.
9.
Young AS, Sullivan G, Burnam MA, Brook RH: Measuring the Quality of Outpatient Treatment for Schizophrenia. Arch Gen Psychiatry. 1998, 55: 611-617. 10.1001/archpsyc.55.7.611.CrossRefPubMed
10.
Kroken R, Johnsen E, Ruud T, Wentzel-Larsen T, Jorgensen HA: Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry. 2009
11.
Weinmann S, Janssen B, Gaebel W: Guideline adherence in medication management of psychotic disorders: an observational multisite hospital study. Acta Psychiatr Scand. 2005, 11: 18-25.CrossRef
12.
Johnsen E, Svingen GF, Jørgensen HA: Practice regarding antipsychotic therapy: A cross-sectional survey into Norwegian hospitals. Nord J Psychiatry. 2004, 58: 313-317. 10.1080/08039480410005837.CrossRefPubMed
13.
Patrick V, Schleifer SJ, Nurenberg JR, Gill KJ: An Initiative to Curtail the Use of Antipsychotic Polypharmacy in a State Psychiatric Hospital. Psychiat Serv. 2006, 57: 21-23. 10.1176/appi.ps.57.1.21.CrossRef
14.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV. 1994, American Psychiatric Association, Washington DC, 4
15.
Ringen PA, Melle I, Birkeneaes AB, Engh JA, Faerden A, Vaskin A, et al: The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatric Scand. 2008, 118: 297-304. 10.1111/j.1600-0447.2008.01244.x.CrossRef
16.
Birkenaes AB, Søgaard AJ, Engh JA, Jonsdottir H, Ringen A, Vaskin A, et al: Sociodemographic Characteristics and Cardiovascular Risk Factors in Patients with Severe Mental Disorders Compared With the General Population. J Clin Psychiatry. 2006, 67: 425-433. 10.4088/JCP.v67n0314.CrossRefPubMed
17.
Jònsdòttir H, Opjordsmoen S, Birkenaes AB, Engh JA, Ringen PA, Vaskin A, et al: Medication adherence in outpatients with severe mental disorders: Relation between self-reports and serum-level. Journal of Clinical Psychopharmacology. 2010, 30: 169-175. 10.1097/JCP.0b013e3181d2191e.CrossRefPubMed
18.
First MB, Spitzer RL, Gibbon M: Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID I/P, version 2.0). 1995, New York: New York State Psychiatric Institute, Biometrics Research Dept
19.
Pedersen G, Hagtvedt KA, Karterud S: Generalizability studies of the Global Assessment of Functioning-Split version. Compr Psychiatry. 2007, 48 (1): 88-94. 10.1016/j.comppsych.2006.03.008.CrossRefPubMed
20.
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, WFSBP Task Force on Treatment Guidelines for Schizophrenia: WFSBP- guidelines for biological treatment of schizophrenia part -2. Long-term treatment of schizophrenia. World J Biol Psychiatry. 2006
21.
Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, et al: Advantages and disadvantages of combination treatment with antipsychotics. ECNP Consensus Meeting, March 2008. Eur Neuropsychopharmacology. 2009, 19: 520-532. 10.1016/j.euroneuro.2009.04.003.CrossRef
22.
Kreyenbuhl JA, Valenstein M, McCarty JF, Granoczy D, Blow FC: Long-Term Antipsychotic Polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv. 2007, 58: 489-495. 10.1176/appi.ps.58.4.489.CrossRefPubMedPubMedCentral
23.
Ballerini A, Baccalon RM, Boncompagni G, Casacchia M, Margari F, Minervini L, et al: Main clinical features in patients at their first psychiatric admission to Italian acute hospital psychiatric wards. The PERSEO study. BMC Psychiatry. 2007, 7: 3-10.1186/1471-244X-7-3.CrossRefPubMedPubMedCentral
24.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med. 2005, 353 (12): 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed
25.
Stahl SM, Grady MM: A critical review of atypical antipsychotic utilization: - comparing monotherapy with polypharmacy and augmentation. Curr Medicinal Chemistry. 2004, 11: 313-327. 10.2174/0929867043456070.CrossRef
26.
Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E: Benefit and Risk of Antipsychotic Polypharmacy. An Evidence-Based Review of the Literature. Drug Safety. 2008, 31: 7-20. 10.2165/00002018-200831010-00002.CrossRefPubMed
27.
Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S: Antipsychotic Combinations vs. Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr Bull. 2009, 35: 443-457. 10.1093/schbul/sbn018.CrossRefPubMed
Metadata
Title
Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia
Authors
Albert Bolstad
Ole A Andreassen
Jan I Røssberg
Ingrid Agartz
Ingrid Melle
Lars Tanum
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2011
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-11-126

Other articles of this Issue 1/2011

BMC Psychiatry 1/2011 Go to the issue

Study protocol

Disrupting the rhythm of depression: design and protocol of a randomized controlled trial on preventing relapse using brief cognitive therapy with or without antidepressants

Study protocol

Exercise augmentation compared to usual care for Post Traumatic Stress Disorder: A Randomised Controlled Trial (The REAP study: Randomised Exercise Augmentation for PTSD)

Research article

Outcomes for depression and anxiety in primary care and details of treatment: a naturalistic longitudinal study

Research article

A cross-sectional testing of The Iowa Personality Disorder Screen in a psychiatric outpatient setting

Research article

Self-esteem is associated with premorbid adjustment and positive psychotic symptoms in early psychosis

Research article

Use of NON-PARAMETRIC Item Response Theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS)